Design: Systematic review and meta-analysis of 4 randomised trials
Population: 1,872 patients with gastrointestinal cancers
Primary outcome: Risk of key adverse events vs control
Effect: Grade ≥3 hypertension RR 9.01 (4.67–17.4); grade ≥3 HFSR RR 26.0; proteinuria RR 1.89

A meta-analysis in Oncology Research (14 September) pooled four randomised trials of fruquintinib, a selective VEGFR-1/2/3 inhibitor, in gastrointestinal cancers, with 1,872 patients.

Fruquintinib increased grade 3 or higher hypertension about ninefold (RR 9.01, 95% CI 4.67–17.4) and grade 3 or higher hand-foot skin reaction far more (RR 26.0, 6.42–105). Any-grade proteinuria nearly doubled (RR 1.89, 1.30–2.74). Severe bleeding was uncommon and not significantly increased (RR 1.82, 0.92–3.61), and venous thromboembolism estimates were too imprecise to interpret.

None of these are surprising for a VEGFR inhibitor, but the sizes help prioritise. Most severe toxicity is predictable and manageable if blood pressure, skin and urine are watched from the start, which is what keeps patients on a drug used late in metastatic colorectal cancer.

Control blood pressure before starting and check it weekly in the first cycle
Start urea-based emollients and advise on footwear from day one
Dipstick urine for protein before each cycle
Ask about bleeding history and anticoagulant use before starting
Agree dose-hold rules with the patient so severe toxicity is reported early

Why it matters

Knowing which toxicities are common lets teams prevent the ones that end treatment early.

The statistics, in plain English

Very large risk ratios like 26 come from few events in the control arm, so the interval is wide (6 to 105); the direction is certain, the exact size is not. The bleeding interval crosses 1, so an increase is possible but unproven.